Alfredo Addeo
Département d'Oncologie Hôpitaux Universitaires de Genève · University Hospital, Geneva · Hôpitaux Universitaires Genève
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alfredo Addeo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:39 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06068153 · AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLCETOP IBCSG Partners Foundation · withdrawn · Metastatic Non Small Cell Lung Cancer, KRAS G12C · study chair
- N/ANCT05421936 · Osimertinib for NSCLC With Uncommon EGFR MutationsSheba Medical Center · suspended · Carcinoma, Non-Small-Cell Lung, Genes, erbB-1 · principal investigator
- Ph2NCT04472949 · Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).Swiss Cancer Institute · active not recruiting · Small Cell Lung Cancer, Lung Cancer · study chair
- Ph2NCT03762122 · Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)Swiss Cancer Institute · terminated · Squamous-cell Non-small Cell Lung Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:39 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:39 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- 31 citationsRCR 1.9
- Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer.Ann Oncol · 200421 citationsRCR 0.5
- 20 citationsRCR 1.2
- Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?Lung Cancer · 200819 citationsRCR 0.5
- Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.Anticancer Res · 201818 citationsRCR 0.6
- SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.Cancer Immunol Immunother · 202115 citationsRCR 0.7
- Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial.Cancer Chemother Pharmacol · 200612 citationsRCR 0.4
- Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy.Anticancer Res · 200510 citationsRCR 0.3
- Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial.Lung Cancer · 20258 citationsRCR 1.6
- 7 citationsRCR 0.2